CEO: Mark J. Foley

Sector: Health Technology

Exchange: NASDAQ

Country: US

Description: Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.


Key numbers

Market Capitalization:1385631734
Shares Outstanding: 57115900
Float: 51836849
Next Earning Date:2020-10-29
TTm EPS: -3.9634
TTm Dividend Rate:
200 days moving average:19.51
50 days moving average: 23.37
One day percent Change: 4.34



2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,